Integration not isolation: Arguing the case for quantitative and systems pharmacology in drug discovery and development

Drug Discovery Today

Volumn 16, Issue 23-24, 2011, Pages 1031-1036

  Agoram, Balaji M ^a   Demin, Oleg ^b  

^a MEDIMMUNE   (United States)

^b Institute for Systems Biology SPb   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DRUG RESEARCH; HUMAN; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; QUANTITATIVE ANALYSIS; REVIEW; SYSTEMS BIOLOGY;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PHARMACOLOGY; SYSTEMS BIOLOGY;

EID: 82255183162     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.10.001     Document Type: Review

References (30)

1. S.R. Allerheiligen Next-generation model-based drug discovery and development: quantitative and systems pharmacology Clin. Pharmacol. Ther. 88 2010 135 137
2. R.L. Lalonde Model-based drug development Clin. Pharmacol. Ther. 82 2007 21 32 (Pubitemid 46950619)
3. P.K. Kreeger, and D.A. Lauffenburger Cancer systems biology: a network modeling perspective Carcinogenesis 31 2010 2 8
4. I. Nestorov Whole body pharmacokinetic models Clin. Pharmacokinet. 42 2003 883 908 (Pubitemid 36995260)
5. M. Rowland Physiologic pharmacokinetic models and interanimal species scaling G. Tucker, Pharmacokinetics: Theory and Methodology. International Encyclopedia of Pharmacology and Therapeutics, Section 122 1986 Pergamon Pr 69 88
6. H.M. Jones Modelling and PBPK simulation in drug discovery AAPS J. 11 2009 155 166
7. P. Poulin, and F.P. Theil A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery J. Pharm. Sci. 89 2000 16 35 (Pubitemid 30080151)
8. B. Agoram Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv. Drug Deliv. Rev. 50 Suppl. 1 2001 S41 S67
9. M. Jamei A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates Drug Metab. Pharmacokinet. 24 2009 53 75
10. L.T. Baxter Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model Cancer Res. 55 1995 4611 4622
11. V. Ghetie Increasing the serum persistence of an IgG fragment by random mutagenesis Nat. Biotechnol. 15 1997 637 640 (Pubitemid 27291163)
12. L. Jerby Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism Mol. Syst. Biol. 6 2010 401
13. A. Raghunathan Systems approach to investigating host-pathogen interactions in infections with the biothreat agent Francisella. Constraints-based model of Francisella tularensis BMC Syst. Biol. 4 2010 118
14. M. Noble The kinetic model of the shikimate pathway as a tool to optimize enzyme assays for high-throughput screening Biotechnol. Bioeng. 95 2006 560 573 (Pubitemid 44671460)
15. G.M. Davies (6S)-6-fluoroshikimic acid, an antibacterial agent acting on the aromatic biosynthetic pathway Antimicrob. Agents Chemother. 38 1994 403 406 (Pubitemid 24054276)
16. J.C. Egrie Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin Exp. Hematol. 31 2003 290 299 (Pubitemid 36407605)
17. C.A. Sarkar, and D.A. Lauffenburger Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo Mol. Pharmacol. 63 2003 147 158 (Pubitemid 36043818)
18. A.W. Gross, and H.F. Lodish Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP) J. Biol. Chem. 281 2006 2024 2032 (Pubitemid 43845790)
19. P. Qiu Dependence network modeling for biomarker identification Bioinformatics 23 2007 198 206 (Pubitemid 46189610)
20. A.M. Latham An integrative model for vascular endothelial growth factor A as a tumour biomarker Integr. Biol. (Camb) 2 2010 397 407
21. P. Budu-Grajdeanu Mathematical framework for human SLE Nephritis: disease dynamics and urine biomarkers Theor. Biol. Med. Model 7 2010 14
22. B. Svensson Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial Arthritis Rheum. 52 2005 3360 3370 (Pubitemid 41612202)
23. J.C. Earp Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis J. Pharmacol. Exp. Ther. 326 2008 546 554
24. J.C. Earp Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats J. Pharmacol. Exp. Ther. 326 2008 532 545
25. M.C. Liu Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group J. Allergy Clin. Immunol. 98 5 Pt 1 1996 859 871 (Pubitemid 26405886)
26. M.C. Peterson, and M.M. Riggs A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling Bone 46 2010 49 63
27. A. Marathe Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients J. Pharmacol. Exp. Ther. 326 2008 555 562
28. P. Vicini Multiscale modeling in drug discovery and development: future opportunities and present challenges Clin. Pharmacol. Ther. 88 2010 126 129
29. G. Cedersund, and P. Stralfors Putting the pieces together in diabetes research: towards a hierarchical model of whole-body glucose homeostasis Eur. J. Pharm. Sci. 36 2009 91 104
30. C. Dalla Man Meal simulation model of the glucose-insulin system IEEE Trans. Biomed. Eng. 54 2007 1740 1749 (Pubitemid 47450539)